Celltrion

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• Celltrion obtains U.S. Phase 3 clinical trial approval for ‘Zymfentra’ seeking expansion for rheumatoid arthritis indications (öffnet in neuem Tab)

  더바이오 · 02.10.2026

• Celltrion to Expand Global Supply Chain and CDMO Partnerships at CPHI, Accelerating Push to Become Global Drugmaker (öffnet in neuem Tab)

  v.daum.net · 29.09.2026

• Celltrion wins U.S. Phase 3 clinical trial approval for ‘Zymfentra’ in rheumatoid arthritis, expanding indications (öffnet in neuem Tab)

  더바이오 · 27.09.2026

• How Celltrion's Remsima Became Japan's Top Infliximab: A 2026 Market Analysis (öffnet in neuem Tab)

  뉴스1 · 18.09.2026

• Celltrion Submits U.S. Phase 4 IND for High-Dose 240 mg Zymfentra (öffnet in neuem Tab)

  뉴스1 · 16.09.2026

• Celltrion Launches U.S. Phase 4 Trial of High-Dose Zymfentra (öffnet in neuem Tab)

  팜이데일리 · 15.09.2026

• “Second-Half Performance to Outpace First Half”… Celltrion Expected to Exceed Full-Year Revenue Target (öffnet in neuem Tab)

  뉴스1 · 04.09.2026